Protocol Ledger

NCT05742607 · Phase II · RECRUITING

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Interventional Phase II clinical trial protocol NCT05742607 sponsored by Innate Pharma in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-23 Enrollment: 70 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05742607
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)70 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05742607
Protocol FieldVerified Registry Value
NCT IdentifierNCT05742607
Consolidated Lead SponsorInnate Pharma
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment70 participants (ESTIMATED)
Registered Start Date2023-06-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05742607
Hospital Research SiteLocationSite Profile
Moffitt Cancer CenterTampa, FLOpen Hospital Dossier ->
University of Chicago MedicineChicago, ILOpen Hospital Dossier ->
Gustave RoussyVillejuif, FranceOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI